Immatics (NASDAQ:IMTX) Sets New 12-Month Low - Should You Sell?

Immatics (NASDAQ:IMTX - Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $5.27 and last traded at $5.31, with a volume of 113573 shares changing hands. The stock had previously closed at $5.34.

Analyst Ratings Changes

A number of analysts have weighed in on the company. The Goldman Sachs Group upgraded Immatics to a "strong-buy" rating in a research note on Monday, November 25th. Bank of America lowered their price objective on shares of Immatics from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, November 19th. Finally, Piper Sandler started coverage on shares of Immatics in a research report on Monday, October 7th. They set an "overweight" rating and a $19.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $16.67.

Immatics Trading Down 0.2 %

The business's 50-day simple moving average is $6.95 and its 200 day simple moving average is $9.50. The firm has a market cap of $636.19 million, a PE ratio of -8.08 and a beta of 0.77.

Institutional Trading of Immatics

Hedge funds have recently bought and sold shares of the stock. abrdn plc raised its position in shares of Immatics by 49.2% in the 4th quarter. abrdn plc now owns 347,379 shares of the company's stock worth $2,470,000 after acquiring an additional 114,479 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in shares of Immatics by 17.5% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,354,711 shares of the company's stock valued at $15,457,000 after buying an additional 202,255 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Immatics by 1.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,681,183 shares of the company's stock valued at $110,462,000 after buying an additional 144,549 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Immatics during the 3rd quarter worth approximately $114,000. Finally, State Street Corp raised its stake in shares of Immatics by 11.2% during the 3rd quarter. State Street Corp now owns 225,202 shares of the company's stock worth $2,570,000 after acquiring an additional 22,710 shares in the last quarter. Hedge funds and other institutional investors own 64.41% of the company's stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.